GLP-1 Medications and Asthma: What the Research Shows

*This article is for informational and educational purposes only. It is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved medications. The clinical research cited here was conducted using FDA-approved branded formulations. Results from studies of FDA-approved medications may not apply to compounded products. Individual results vary. Consult your licensed healthcare provider, pulmonologist, and allergist before starting, stopping, or adjusting any medication. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or employ physicians.*

---

About 25 million Americans have asthma, and the condition is disproportionately common among people living with obesity. The connection between body weight and lung health runs deeper than most people realize. Excess weight does not just make breathing feel harder physically; it reshapes the immune environment of the airways in ways that can make asthma more severe and harder to control with standard inhalers alone.

GLP-1 receptor agonists have transformed weight management over the past several years. As their use expanded, researchers noticed something unexpected: people on these medications seemed to have fewer asthma flare-ups. A growing body of research is now examining whether that pattern is real, why it might occur, and whether the benefit extends beyond what weight loss alone could explain.

Here is what the current evidence shows, what it does not yet prove, and what it means for anyone managing both asthma and body weight.

---

Why Obesity Makes Asthma Worse

The relationship between obesity and asthma is not simply mechanical. Excess weight changes asthma at multiple levels simultaneously.

Lung mechanics. Fat tissue around the chest and abdomen compresses the lungs and reduces functional lung volume. People with obesity tend to breathe at lower lung volumes where airways are naturally narrower and more prone to closing. This can make the airways hyperresponsive to triggers that a person at a healthy weight might tolerate without symptoms.

Chronic inflammation. Visceral fat (the fat stored around internal organs) releases pro-inflammatory molecules including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). This systemic low-grade inflammation primes the airways for exaggerated immune responses, even in the absence of an allergen.

Immune dysregulation. Adipokines, the signaling proteins released by fat tissue, shift the immune system toward a pro-inflammatory state. Leptin levels are elevated in obesity and drive airway inflammation, while adiponectin, which has anti-inflammatory properties, is often reduced.

Comorbidities that amplify asthma. Gastroesophageal reflux disease (GERD), obstructive sleep apnea, and metabolic syndrome are all more prevalent with obesity and each can independently worsen asthma control. GERD triggers micro-aspiration of acid that irritates airways. Sleep apnea fragments restorative sleep and sustains systemic inflammation overnight.

A 2024 review in the American Journal of Respiratory and Critical Care Medicine described obesity-related asthma as a distinct clinical phenotype with different underlying drivers than classic allergic asthma, and often less responsive to the inhaled corticosteroids that work well for traditional eosinophilic asthma (PMID 39311907). For these patients, addressing obesity directly may matter as much as optimizing inhaler therapy.

---

What GLP-1 Medications Do

GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone your gut releases after eating. The hormone tells your brain you are full, slows stomach emptying, and regulates blood sugar. Medications that activate GLP-1 receptors use these effects to reduce appetite substantially and produce sustained weight loss.

Semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound) are the two GLP-1-based medications currently approved for weight management. In clinical trials, they produced 15 to 22 percent average body weight reductions over 68 weeks, results that have not been matched by previous weight management medications.

What makes GLP-1 receptors particularly relevant to lung health is their distribution throughout the body. GLP-1 receptors are expressed not just in the gut and brain but also in lung tissue, airway smooth muscle cells, and immune cells including macrophages and dendritic cells. That wider distribution prompted researchers to ask whether GLP-1 medications might have direct respiratory effects beyond what weight loss alone could produce.

---

What the Research Shows

The Harvard Cohort Studies: Fewer Exacerbations in Real-World Patients

The strongest observational evidence comes from a series of studies by Dr. Dinah Foer and colleagues at Brigham and Women's Hospital in Boston.

A 2021 analysis in the American Journal of Respiratory and Critical Care Medicine compared patients with type 2 diabetes and asthma who were taking GLP-1 receptor agonists against those on other diabetes medications. People on GLP-1 receptor agonists had significantly fewer severe asthma exacerbations requiring emergency visits or hospitalizations (PMID 33052715).

A 2023 follow-up from the same group extended the analysis to COPD (chronic obstructive pulmonary disease) and found a similar pattern: GLP-1 receptor agonist users had fewer COPD exacerbations compared to matched controls on other diabetes medications (PMID 37647574). The consistency across two different obstructive lung diseases pointed toward a mechanism that went beyond coincidence.

These are observational studies, meaning researchers are comparing groups rather than running controlled experiments. Confounders are always possible: people selected for GLP-1 therapy may differ in ways not fully captured in the data. But the size of the associations and their consistency prompted larger-scale analyses.

Systematic Reviews and JAMA Internal Medicine Findings

A 2025 systematic review published in Respiratory Medicine pooled data from 14 studies examining GLP-1 receptor agonists and respiratory exacerbations in adults with diabetes. The pooled analysis found that GLP-1 receptor agonist use was associated with reduced risk of both asthma and COPD exacerbations, with effects appearing largest in patients with higher BMI (PMID 40480531).

A 2025 study in JAMA Internal Medicine, using a large administrative claims database, compared asthma attack rates between people on GLP-1 receptor agonists and those on other antidiabetic medications. GLP-1 receptor agonist users had lower rates of asthma attacks, a finding that held across demographic subgroups (PMID 39556360).

Which Patients Appear to Benefit Most

Not all asthma is the same, and the emerging evidence suggests the benefits of GLP-1 therapy are not evenly distributed.

A 2024 analysis in the Annals of the American Thoracic Society looked at clinical predictors of who showed the largest reductions in asthma exacerbations with GLP-1 use. Patients with higher BMI, metabolic-driven asthma (rather than allergic asthma), and lower blood eosinophil counts (a marker typically elevated in allergic asthma) showed the strongest benefit signals (PMID 39012183).

This pattern makes biological sense. GLP-1 medications are particularly well suited to addressing the obesity-driven, non-eosinophilic asthma phenotype, which is driven by systemic inflammation and mechanical compression rather than allergic sensitization and IgE-mediated responses.

Patients with classic allergic asthma who are already at a healthy weight are unlikely to see significant respiratory benefit from GLP-1 medications.

---

How GLP-1 Medications May Help the Airways

Current research points to several overlapping pathways that may explain the observed respiratory benefits.

Weight-mediated effects. Losing 10 to 15 percent of body weight reduces mechanical chest compression, improves functional lung volumes, and lowers circulating inflammatory markers like IL-6 and CRP. For asthma driven primarily by obesity mechanics, sustained weight loss may explain most of the observed benefit.

Direct effects on airway inflammation. GLP-1 receptors on macrophages and airway smooth muscle cells may be activated directly by GLP-1 medications, reducing cytokine production and dampening inflammatory signaling independent of weight loss. Laboratory research supports this possibility, though definitive proof in humans awaits well-designed clinical trials.

Reduced GERD. GLP-1 medications slow gastric emptying, which can reduce acid reflux frequency and severity. In patients whose asthma is partly driven by reflux-related airway irritation, better GERD control may improve asthma symptoms indirectly.

Improved sleep apnea. The 2024 SURMOUNT-OSA trial found that tirzepatide significantly reduced the severity of obstructive sleep apnea. People with poorly controlled sleep apnea have higher systemic inflammation and worse asthma control. GLP-1 treatment that addresses sleep apnea could have downstream respiratory benefits.

A 2026 review in Current Opinion in Pulmonary Medicine characterized GLP-1 receptor agonists as targeting the "metabolic-inflammatory crossroads" in asthma: the intersection where obesity, insulin resistance, and airway inflammation converge, creating a disease phenotype that standard asthma therapies do not fully address (PMID 41664500).

---

Clinical Trials Currently Underway

Observational research establishes associations. Only clinical trials can test causation.

As of 2026, at least one formal proof-of-concept clinical trial is testing semaglutide directly in patients with poorly controlled asthma and obesity. A 2026 paper in the Journal of Allergy and Clinical Immunology: Global published the design of this trial, which enrolls patients who are obese, have asthma that is not well controlled despite standard therapy, and have not achieved sustained weight loss through other means. Primary endpoints include lung function measures (FEV1, FVC), asthma control questionnaire scores, and exacerbation rates (PMID 41567689).

Results from this trial will be the strongest test yet of whether semaglutide improves asthma outcomes through mechanisms beyond weight loss, or whether the weight loss itself accounts for the benefit. Either answer will be clinically valuable.

---

Important Caveats

The evidence is encouraging, but several limitations need to be stated plainly.

Most research involves patients with diabetes. The cohort studies described above enrolled people with type 2 diabetes, a group with higher rates of both obesity and inflammatory comorbidities. Whether the findings extend equally to non-diabetic patients with obesity and asthma is not yet established.

GLP-1 medications are not asthma treatments. These medications are prescribed for type 2 diabetes and weight management. Using them specifically to manage asthma, outside of an established treatment program or clinical trial, would be off-label. Any decisions about asthma therapy should involve a pulmonologist or board-certified allergist.

Compounded formulations are not FDA-approved. Compounded semaglutide and tirzepatide are not FDA-approved. All research cited in this article used FDA-approved branded medications. Results may not apply to compounded formulations. Individual results vary significantly.

Allergic asthma is different. Patients with eosinophilic or allergic asthma phenotypes, particularly those already at a healthy weight, have not shown consistent benefit in the current research. The benefit is concentrated in metabolic-driven obesity-related asthma.

---

What This Means If You Have Asthma and Are Managing Your Weight

If your asthma is poorly controlled despite standard therapy and you also have obesity, the emerging research suggests that effective weight management may be one of the most impactful interventions available to you. GLP-1 receptor agonists are currently among the most effective tools for achieving and sustaining clinically meaningful weight loss.

That connection does not make GLP-1 medications an asthma therapy. It does suggest a conversation with your healthcare team about whether addressing obesity medically should be part of your overall respiratory care plan.

For people already considering GLP-1 medications for weight management, the potential for reduced asthma exacerbations is a relevant secondary benefit worth discussing with both your weight management provider and your pulmonologist or allergist.

---

Key Takeaways

• Obesity worsens asthma through mechanical, inflammatory, and immune mechanisms, creating a distinct phenotype that often responds poorly to standard inhaled corticosteroid therapy
• Multiple observational studies and a 2025 systematic review found GLP-1 receptor agonist use was associated with fewer asthma and COPD exacerbations in patients with diabetes and obesity
• Benefits appear most pronounced in metabolic or obesity-driven asthma, not classic allergic or eosinophilic asthma
• A clinical trial is currently testing semaglutide directly in obese patients with poorly controlled asthma, with results expected to clarify mechanism and magnitude of benefit
• GLP-1 medications are prescribed for weight management, not asthma; speak with your healthcare providers about how weight management fits into your broader respiratory care

Ready to explore your options? [Check your eligibility](/start) for Prescriva's medically supervised weight management program.

---

Sources

1. Foer D, et al. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists. *Am J Respir Crit Care Med*. 2021;204(1):73-82. PMID 33052715

1. Foer D, et al. Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes. *Am J Respir Crit Care Med*. 2023;208(10):1088-1099. PMID 37647574

1. Althoff MD, et al. Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches. *Am J Respir Crit Care Med*. 2024;210(10):1186-1196. PMID 39311907

1. Wang T, Foer D. Glucagon-like Peptide 1 Receptor Agonists and Asthma Exacerbations: Which Patients Benefit Most? *Ann Am Thorac Soc*. 2024;21(11):1469-1471. PMID 39012183

1. Cooper DH, et al. Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review. *Respir Med*. 2025;232:107763. PMID 40480531

1. Lee B, et al. Antidiabetic Medication and Asthma Attacks. *JAMA Intern Med*. 2025;185(1):83-91. PMID 39556360

1. O'Brien H, et al. GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads. *Curr Opin Pulm Med*. 2026;32(3). PMID 41664500

1. Tomasello A, et al. Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma. *J Allergy Clin Immunol Glob*. 2026;5(2):100399. PMID 41567689